共 214 条
[1]
Siegel R(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29
[2]
Ma J(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388
[3]
Zou Z(2009)Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene. 28 S24-S31
[4]
Jemal A(2013)Afatinib, Erlotinib and Gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review Oncol Research and Treatment 36 510-518
[5]
Maemondo M(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-957
[6]
Inoue A(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121-128
[7]
Kobayashi K(2015)AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N Engl J Med 372 1689-1699
[8]
Sugawara S(2005)Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 22-933
[9]
Oizumi S(2012)HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation Cancer Discov 2 922-928
[10]
Isobe H(2017)Distinct Afatinib resistance mechanisms identified in lung adenocarcinoma harboring an EGFR mutation Mol Cancer Res 15 915-EE31